In a report released yesterday, Mohit Bansal from Wells Fargo maintained a Hold rating on Biogen (BIIB – Research Report), with a price target of $165.00.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Mohit Bansal has given his Hold rating due to a combination of factors impacting Biogen’s financial outlook. The company’s 2025 guidance fell short of analyst expectations, forecasting a more significant decline in revenue than anticipated by the market. This discrepancy, amounting to approximately a $200 million difference, suggests potential challenges for Biogen in sustaining growth, particularly concerning its new product launches.
Bansal also notes concerns arising from Biogen’s fourth-quarter results, especially with Skyclarys showing a notable decline in the U.S. market. Despite cost-saving measures being on track, the lack of growth in certain areas and the external pressures, such as foreign exchange headwinds, contribute to a cautious outlook. The focus remains on how Biogen addresses these challenges and manages operational expenses while exploring business development opportunities to drive future growth.
In another report released yesterday, Stifel Nicolaus also maintained a Hold rating on the stock with a $144.00 price target.
BIIB’s price has also changed moderately for the past six months – from $201.040 to $133.430, which is a -33.63% drop .